Related Experiment Video
Updated: Feb 24, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.9K
Tocilizumab (Actemra)
Martin Sheppard1, Faidra Laskou1, Philip P Stapleton1
1a Southend University Hospital NHS Foundation Trust , Westcliff on Sea , UK.
Human Vaccines & Immunotherapeutics
|August 26, 2017
Summary
Tocilizumab (TCZ) is an interleukin-6 receptor (IL-6R) inhibitor used for rheumatoid arthritis and juvenile idiopathic arthritis. This review covers its development, efficacy, and future potential in treating inflammatory conditions like giant cell arteritis.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in various autoimmune diseases.
- Tocilizumab (TCZ) is a monoclonal antibody targeting the IL-6 receptor (IL-6R).
- TCZ is approved for treating rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA), and polyarticular juvenile idiopathic arthritis (pJIA).
Purpose of the Study:
- To provide a comprehensive overview of tocilizumab (TCZ).
- To review the discovery of IL-6 and the development of TCZ.
- To explore the current and future applications of TCZ in treating inflammatory and autoimmune conditions.
Main Methods:
- Literature review of IL-6 discovery, TCZ development, manufacturing, and clinical trials.
- Comparative analysis of TCZ with other biologics for RA, sJIA, and pJIA.
- Exploration of emerging therapeutic roles for IL-6 blockade in conditions like GCA, PMR, and LVV.
Main Results:
- TCZ has demonstrated efficacy and safety in treating RA, sJIA, and pJIA.
- Comparative analysis highlights TCZ's advantages and disadvantages against other biologics.
- Emerging evidence suggests TCZ's potential in treating giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and large vessel vasculitis (LVV).
Conclusions:
- Tocilizumab is an effective biologic therapy for established indications.
- IL-6 blockade represents a promising therapeutic strategy for various inflammatory diseases.
- Further research is warranted to fully elucidate the role of TCZ in GCA, PMR, and LVV.
Keywords:
giant cell arteritisinterleukin-6monoclonal antibodyrheumatoid arthritistocilizumabvasculitisMore Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
565
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
565
01:30Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K